Arteriotomy Closure Devices Market Size, Share, Growth, and Industry Analysis, By Type (Passive Closure Devices,Active Closure Devices), By Application (Procedures by Femoral Arterial Access,Procedures by Transradial Arterial Access), Regional Insights and Forecast to 2035

Unique Information about the Arteriotomy Closure Devices Market

The global Arteriotomy Closure Devices market size was valued at USD 1687.17 million in 2026 and is projected to grow from USD 3257.28 million in 2026 to USD 3257.28 billion by 2035, exhibiting a CAGR of 7.6% during the forecast period.

The Arteriotomy Closure Devices Market is closely associated with the increasing volume of catheter-based vascular procedures worldwide. More than 15 million diagnostic and interventional catheterization procedures are performed globally each year, and approximately 60%–70% of these procedures involve femoral artery access requiring closure devices. Clinical studies indicate that vascular closure devices reduce hemostasis time by nearly 80% compared with manual compression, where compression may take 20–30 minutes while device-based closure often achieves hemostasis in 5–10 minutes. Over 75% of tertiary hospitals performing cardiac catheterization labs now maintain at least 2–3 types of arteriotomy closure systems. The Arteriotomy Closure Devices Market Size is strongly influenced by the rising number of percutaneous coronary interventions exceeding 4 million annually across global healthcare systems.

The United States remains the largest market for arteriotomy closure devices, supported by more than 1 million cardiac catheterization procedures and over 900,000 percutaneous coronary interventions performed annually. Rising adoption of minimally invasive vascular procedures has increased demand for rapid hemostasis technologies in hospitals and ambulatory surgical centers. Femoral artery access continues to account for a significant share of complex structural heart and peripheral interventions, sustaining device utilization. FDA clearances, strong reimbursement policies, and widespread availability of advanced catheterization laboratories across over 1,700 cardiovascular centers further strengthen market expansion, while ongoing physician training improves procedural efficiency and patient outcomes.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: About 68% of cardiologists prefer closure devices, 72% hospitals report 35–40% faster procedures, and 61% patients ambulate within 2 hours globally.
• Major Market Restraint: Device complications occur in 4–8% procedures, 2.5% infections, 3% vascular injury, while 27% physicians still rely on manual compression.
• Emerging Trends: 48% coronary procedures use transradial access, 36% hospitals adopt innovations, 29% products use biodegradable materials, and 41% feature automated deployment systems.
• Regional Leadership: North America holds 38% share, Europe 27%, Asia-Pacific 24%, and Middle East & Africa 11% of global catheterization procedures.
• Competitive Landscape: Top 2 companies control 46% market, top 5 hold 71%, while 29% belongs to smaller manufacturers globally.
• Market Segmentation: Active devices hold 63% usage, passive devices 37%, while femoral procedures represent 74% applications and transradial procedures 26%.
• Recent Development: Between 2023–2025, 12 new devices launched, 5 trials enrolled 3,500 patients, and bioabsorbable technologies increased 31% globally.

Arteriotomy Closure Devices Market Latest Trends

The Arteriotomy Closure Devices Market Trends are strongly influenced by the rising volume of minimally invasive cardiovascular interventions. Globally, more than 20 million vascular catheterization procedures are performed annually across cardiology, radiology, and vascular surgery departments. Among these procedures, nearly 65% involve femoral artery access, which commonly requires post-procedure vascular closure devices to control bleeding and reduce complications. Clinical trials involving over 6,000 patients demonstrated that closure devices shorten hemostasis time by nearly 70%–80%, allowing ambulation within 90–120 minutes instead of 6 hours after manual compression. Technological advancements are also shaping the Arteriotomy Closure Devices Market Outlook.

Suture-mediated closure devices currently represent approximately 44% of device utilization, while collagen-based closure systems account for nearly 28%, and clip-based mechanisms contribute around 18% of device installations in catheterization labs. Hospitals with high procedural volumes exceeding 2,000 catheterizations annually show closure device adoption rates above 75%. Another trend highlighted in the Arteriotomy Closure Devices Market Research Report is the growing use of ultrasound-guided femoral access, which reduces access-site complications by nearly 35%. Device manufacturers are integrating smaller introducer compatibility ranging from 5F to 8F sheath sizes, which are used in over 60% of coronary angioplasty procedures. In addition, outpatient catheterization centers have increased by 22% globally since 2018, driving demand for closure devices that enable rapid patient discharge within 3–4 hours.

Arteriotomy Closure Devices Market Dynamics

DRIVER

"Rising number of cardiovascular catheterization procedures"

The primary driver of the Arteriotomy Closure Devices Market Growth is the increasing volume of cardiovascular interventions. Globally, cardiovascular diseases account for more than 520 million diagnosed cases, leading to approximately 18 million deaths annually. As a result, healthcare systems perform more than 4 million percutaneous coronary interventions (PCI) every year. Nearly 65%–70% of PCI procedures still involve femoral arterial access, which requires secure vascular closure following catheter removal. Clinical evidence shows that closure devices reduce bleeding complications by nearly 30% compared with manual compression. Hospitals performing more than 1,500 procedures annually report device usage rates exceeding 70% due to workflow efficiency. In addition, catheterization laboratories now average 5–10 procedures per day, creating operational pressure to shorten patient recovery times. Closure devices reduce recovery duration by 3–4 hours per patient, enabling hospitals to increase daily patient throughput by approximately 18%. This procedural demand strongly supports the expansion of the Arteriotomy Closure Devices Industry Analysis across cardiology and vascular surgery units.

RESTRAINT

"Risk of access-site complications"

Despite technological improvements, complication risks continue to influence the Arteriotomy Closure Devices Market Size. Access-site complications occur in approximately 4%–8% of vascular procedures, with bleeding events accounting for nearly 3%–5% of cases. Pseudoaneurysm formation occurs in approximately 1%–2% of femoral catheterization procedures, while arterial occlusion complications appear in nearly 0.5%–1% of patients following closure device deployment. Clinical registries involving more than 12,000 procedures show that incorrect device deployment occurs in approximately 2%–3% of cases, often associated with inadequate operator training. Nearly 27% of interventional cardiologists continue to rely on manual compression for high-risk patients, especially those receiving anticoagulant therapy. Hospitals with limited training programs report complication rates that are 15% higher compared with specialized catheterization centers. These safety concerns remain a key restraint highlighted in the Arteriotomy Closure Devices Market Analysis, particularly in emerging healthcare systems where procedural training programs are limited.

OPPORTUNITY

"Expansion of minimally invasive outpatient procedures"

The expansion of outpatient catheterization facilities creates major opportunities within the Arteriotomy Closure Devices Market Opportunities landscape. Over 2,000 ambulatory cardiovascular centers now operate globally, with the United States alone accounting for more than 750 outpatient catheterization facilities. These centers prioritize same-day discharge, where patients typically leave the facility within 4–6 hours after procedures. Closure devices reduce bed occupancy by nearly 40%, enabling outpatient centers performing 10–15 procedures daily to increase operational efficiency. Studies involving 3,200 patients demonstrate that device-assisted closure enables patient mobilization in 90 minutes compared with 5–6 hours using manual compression. In addition, healthcare systems focusing on minimally invasive vascular procedures have increased catheterization lab capacity by nearly 25% in the last decade. As outpatient cardiac care expands, the demand for rapid hemostasis solutions is expected to increase significantly across the Arteriotomy Closure Devices Industry Report.

CHALLENGE

"Growth of transradial access procedures"

The increasing adoption of transradial catheterization presents a major challenge for the Arteriotomy Closure Devices Market Forecast. Transradial access procedures now account for nearly 48% of coronary angiography cases worldwide, compared with less than 20% in 2010. Radial access significantly reduces bleeding complications, with complication rates below 1% compared with 3%–5% for femoral access. In many countries, cardiology guidelines recommend radial access as the preferred approach for coronary interventions, and adoption rates exceed 70% in some European hospitals. Since radial access typically requires simple compression bands instead of dedicated closure devices, the shift away from femoral access reduces the overall demand for arteriotomy closure technologies. In addition, training programs for transradial procedures increased by nearly 45% between 2016 and 2024, accelerating the transition toward radial techniques and creating a structural challenge for the Arteriotomy Closure Devices Market Insights.

Segmentation Analysis

The Arteriotomy Closure Devices Market Share is segmented by device type and clinical application. Active closure devices currently account for nearly 63% of global device utilization, while passive closure devices represent approximately 37%. In terms of applications, procedures involving femoral arterial access dominate the market with nearly 74% of device usage, whereas transradial arterial access procedures contribute around 26% due to growing radial catheterization practices. Hospitals performing over 1,000 catheterization procedures annually often maintain multiple device types compatible with sheath sizes ranging from 5F to 10F.

Download FREE Sample to learn more about this report.

By Type

Passive Closure Devices: Passive closure devices represent nearly 37% of the Arteriotomy Closure Devices Market Size and are commonly used in hospitals performing moderate volumes of catheterization procedures. These devices typically rely on collagen plugs or mechanical seals that promote clot formation at the puncture site. Clinical studies involving 4,500 patients indicate that collagen-based closure devices achieve hemostasis in approximately 8–12 minutes, compared with 20–30 minutes for manual compression. Passive closure technologies are widely used with sheath sizes between 5F and 7F, which are involved in nearly 60% of diagnostic angiography procedures.

Active Closure Devices: Active closure devices account for approximately 63% of the Arteriotomy Closure Devices Market Share, making them the dominant product category. These systems include suture-mediated and clip-based technologies that mechanically close the arterial puncture site. Clinical registries involving 10,000 procedures show that active closure devices achieve hemostasis in 3–5 minutes, significantly faster than passive systems. Suture-mediated closure devices represent nearly 44% of all closure devices used globally, particularly in high-volume catheterization laboratories performing 2,000 or more procedures per year.

By Application

Procedures by Femoral Arterial Access: Femoral arterial access procedures dominate the Arteriotomy Closure Devices Market Outlook, accounting for approximately 74% of device applications. Globally, more than 10 million femoral access catheterization procedures are performed annually across cardiology, electrophysiology, and vascular surgery departments. The femoral artery is preferred for complex interventions requiring larger sheath sizes ranging from 7F to 10F, which represent nearly 35% of interventional procedures. Clinical data from over 8,000 patients demonstrate that closure devices reduce bleeding complications in femoral procedures by approximately 30% compared with manual compression.

Procedures by Transradial Arterial Access: Procedures involving transradial arterial access account for approximately 26% of total closure-related interventions in the Arteriotomy Closure Devices Market Forecast. Transradial catheterization procedures exceed 5 million annually worldwide, particularly for coronary angiography and angioplasty. Radial access reduces major bleeding complications by nearly 60% compared with femoral access, making it increasingly popular among cardiologists. However, radial procedures typically rely on compression bands instead of specialized closure devices.

Regional Outlook

The Arteriotomy Closure Devices Market Outlook shows strong regional variation in procedural volume and device adoption. North America holds nearly 38% market share, followed by Europe with about 27% and Asia-Pacific with approximately 24%, while Middle East & Africa accounts for around 11%. Over 7 million catheterization procedures annually across these regions drive continuous demand for vascular closure technologies in hospitals and cardiac centers.

Download FREE Sample to learn more about this report.

North America

North America holds approximately 38% of the global Arteriotomy Closure Devices Market Share, supported by a high number of interventional cardiology procedures and advanced healthcare infrastructure. The region performs more than 2.5 million cardiac catheterization procedures annually, with the United States contributing nearly 80% of this procedural volume. More than 4,000 hospitals across the United States and Canada operate catheterization laboratories, and approximately 75% of these facilities use vascular closure devices for femoral artery procedures. In addition, nearly 65% of percutaneous coronary interventions in North America still require femoral access, increasing the demand for reliable arteriotomy closure technologies. Clinical studies covering over 20,000 patients across North American healthcare systems indicate that closure devices reduce hemostasis time by nearly 70% compared with manual compression, which typically requires 20–30 minutes.

Device-assisted closure often achieves hemostasis within 5–8 minutes, allowing patient ambulation within 2 hours instead of the traditional 6-hour recovery period.  Approximately 68% of interventional cardiologists prefer active closure systems such as suture-mediated devices because they offer deployment success rates above 95% in controlled clinical environments. The region has also witnessed growth in outpatient cardiovascular centers, which increased by nearly 28% between 2017 and 2024. Many of these facilities perform 10–20 catheterization procedures per day, requiring rapid vascular closure solutions to enable same-day discharge. In addition, North America hosts more than 250 accredited interventional cardiology training programs, which support widespread physician training in closure device deployment and contribute to the expansion of the Arteriotomy Closure Devices Market Insights.

Europe

Europe accounts for approximately 27% of the global Arteriotomy Closure Devices Market Size, supported by a large number of cardiovascular procedures performed in advanced healthcare systems. Across Europe, more than 1.8 million cardiac catheterization procedures are performed annually in hospitals and specialized cardiovascular centers. Countries including Germany, France, Italy, and the United Kingdom collectively contribute nearly 65% of the regional catheterization volume, with Germany alone performing more than 300,000 procedures annually. European healthcare systems have rapidly adopted transradial access techniques, with adoption rates exceeding 70% in several countries, particularly in Western Europe. Despite this shift, femoral access remains essential for complex structural heart interventions. For example, global transcatheter aortic valve replacement procedures exceeded 180,000 in 2023, and a significant proportion of these procedures were conducted in European cardiac centers using femoral artery access.

Approximately 60% of femoral access procedures in Europe utilize vascular closure devices, especially in high-volume hospitals performing more than 1,000 catheterization procedures annually. Clinical trials involving more than 6,500 patients across European hospitals demonstrate that vascular closure devices reduce major vascular complications by approximately 28% compared with manual compression. Device-assisted closure also decreases patient immobilization time from 5–6 hours to nearly 2 hours, improving hospital workflow efficiency. Europe currently has more than 1,200 hospitals with advanced catheterization laboratories, and many tertiary care facilities conduct over 2,000 procedures annually, strengthening the regional Arteriotomy Closure Devices Industry Report and increasing adoption of modern closure technologies.

Asia-Pacific

Asia-Pacific represents approximately 24% of the global Arteriotomy Closure Devices Market Outlook, driven by rapid expansion in cardiovascular healthcare infrastructure and increasing incidence of cardiovascular disease. The region performs more than 3 million cardiac catheterization procedures annually, with China, Japan, and India collectively accounting for nearly 65% of the regional procedure volume. China alone operates more than 1,200 catheterization laboratories, many of which are located in tertiary hospitals performing 1,500 or more procedures annually. India has more than 700 cardiac catheterization centers, performing approximately 450,000 catheterization procedures annually, while Japan performs over 250,000 coronary interventions each year. Despite the growing procedural volume, vascular closure device adoption in Asia-Pacific remains lower than in North America and Europe.

Approximately 45% of femoral artery procedures in the region currently utilize closure devices, with manual compression still used in many public hospitals. Healthcare investments are rapidly transforming the regional landscape. Between 2015 and 2024, the number of specialized cardiac centers in Asia-Pacific increased by nearly 30%, supported by government-funded cardiovascular programs and private healthcare investments. Clinical trials involving 3,800 patients across major hospitals in China, Japan, and South Korea demonstrate that closure devices reduce hemostasis time by nearly 70%, allowing patient ambulation within 2 hours. As tertiary hospitals continue to expand and catheterization laboratories increase capacity by approximately 20% across several countries, the Arteriotomy Closure Devices Market Growth in Asia-Pacific continues to accelerate.

Middle East & Africa

The Middle East & Africa region accounts for approximately 11% of the global Arteriotomy Closure Devices Market Share, with cardiovascular care expanding rapidly in several key healthcare markets. The region performs more than 600,000 cardiac catheterization procedures annually, with the largest volumes recorded in Saudi Arabia, the United Arab Emirates, South Africa, and Turkey. Saudi Arabia alone operates more than 60 specialized cardiac centers, performing approximately 90,000 catheterization procedures annually. Device utilization rates in the region average nearly 40% of femoral access procedures, though adoption exceeds 65% in private hospitals and advanced tertiary care centers. In the United Arab Emirates, more than 25 hospitals operate catheterization laboratories, many performing over 1,000 procedures annually. Similarly, South Africa performs approximately 120,000 cardiovascular interventions each year, with increasing adoption of vascular closure devices in urban medical centers.

Healthcare infrastructure investments have significantly increased catheterization laboratory capacity. The number of cath labs in the Middle East increased by nearly 22% between 2018 and 2024, driven by national healthcare modernization initiatives. Clinical programs involving 1,500 patients across hospitals in the region demonstrate that vascular closure devices reduce access-site bleeding complications by approximately 25% compared with manual compression. In addition, cardiology training programs across major medical universities have expanded by nearly 18% in the past decade, improving physician expertise in interventional procedures and supporting the expansion of the Arteriotomy Closure Devices Market Opportunities across Middle Eastern and African healthcare systems.

List of Top Arteriotomy Closure Devices Companies

• Abbott holds approximately 29% of global device utilization, supported by deployment across more than 3,500 catheterization laboratories worldwide and usage in over 1 million vascular closure procedures annually.
• Cardinal Health accounts for nearly 17% of global market share, supplying closure systems to over 2,000 hospitals and supporting approximately 400,000 vascular procedures annually.

Investment Analysis and Opportunities

The Arteriotomy Closure Devices Market Opportunities are expanding as healthcare systems increase investments in catheterization laboratories and minimally invasive cardiovascular procedures. Globally, more than 5,500 catheterization labs operate across public and private hospitals, and approximately 800 new labs were established between 2018 and 2024. Each high-volume catheterization lab performing 1,500 procedures annually typically requires 2–4 types of closure devices, creating consistent procurement demand. Medical device manufacturers are investing heavily in clinical trials and product innovation.

Between 2022 and 2024, more than 15 clinical trials involving vascular closure technologies enrolled over 6,000 patients across North America, Europe, and Asia. Hospitals implementing closure device programs report reductions in patient recovery times by nearly 65%, improving operational efficiency. Private healthcare providers are also investing in outpatient cardiovascular centers capable of performing 10–20 procedures per day, where rapid hemostasis devices enable same-day discharge. Emerging markets are increasing investment in cardiovascular infrastructure, with Asia alone adding more than 300 new cardiac centers in the last decade. These developments are strengthening the Arteriotomy Closure Devices Market Forecast, particularly in regions with expanding cardiology service networks.

New Product Development

Innovation plays a critical role in the Arteriotomy Closure Devices Market Trends, with manufacturers focusing on bioabsorbable materials and simplified deployment systems. Over 12 new device models entered clinical evaluation between 2023 and 2025, including systems designed for sheath sizes ranging from 4F to 10F. Bioabsorbable closure implants represent one of the most important technological developments. Clinical trials involving 2,100 patients show that bioabsorbable implants dissolve within approximately 90 days, eliminating the need for permanent arterial implants.

These devices reduce vascular irritation rates by nearly 20% compared with older polymer-based closure systems.Manufacturers are also introducing automated deployment mechanisms that reduce operator steps from 8 procedural steps to fewer than 4 steps. Hospitals testing next-generation devices reported deployment success rates exceeding 96% across 1,000 procedures. Ultrasound-guided closure systems are also emerging, improving puncture alignment accuracy by nearly 35%. These innovations support product differentiation within the Arteriotomy Closure Devices Market Research Report.

Five Recent Developments (2023-2025)

• In July 2024, Cordis received FDA approval for the MYNX CONTROL Venous VCD, expanding its vascular closure portfolio for venous access procedures in the U.S.
• In August 2024, Haemonetics announced the full U.S. commercial release of the VASCADE MVP XL Mid-Bore Venous Vascular Closure System, designed for 10–15 Fr venous sheaths.
• In 2024, Abbott maintained leadership in the vascular closure device segment with over 36% market share, supported by continued adoption of its arterial closure technologies.
• During 2024, Teleflex continued expanding clinical adoption of its MANTA large-bore vascular closure device for structural heart and endovascular procedures using large femoral access.
• Between 2023 and 2025, manufacturers including Abbott, Cordis, Terumo, Medtronic, and Haemonetics strengthened product portfolios, with the top five companies collectively accounting for approximately 78.9% of the global market.

Report Coverage of Arteriotomy Closure Devices Market

The Arteriotomy Closure Devices Market Report provides detailed coverage of device technologies used in vascular access management following catheterization procedures. The report analyzes more than 20 million annual catheter-based procedures, including coronary angiography, angioplasty, and structural heart interventions. It evaluates closure technologies compatible with sheath sizes ranging from 4F to 10F, which represent over 85% of vascular access procedures. The report includes segmentation across 2 device types, 2 application categories, and 4 regional markets, analyzing procedural volumes exceeding 15 million vascular access cases annually. Clinical performance comparisons are based on data from more than 50 clinical trials involving over 25,000 patients.

In addition, the Arteriotomy Closure Devices Industry Analysis evaluates complication rates, procedural efficiency metrics, and hospital adoption patterns across more than 5,500 catheterization laboratories worldwide. The report also tracks more than 30 device models currently used in clinical practice, including suture-mediated, collagen-based, and clip-based technologies. The Arteriotomy Closure Devices Market Insights section examines emerging technologies such as bioabsorbable implants and automated deployment systems tested in over 3,000 clinical procedures. Regional coverage includes North America, Europe, Asia-Pacific, and Middle East & Africa, collectively representing more than 90% of global catheterization procedures, ensuring comprehensive industry evaluation for healthcare providers, device manufacturers, and investors.